ICAM1 and breast carcinoma: Interestingly, anti-ICAM1 treatment has been proposed to interfere with tumor progression in multiple myeloma [93,94], lung [95] and breast cancer [96], showing that the targeting of angiocrine factors might be a valid therapeutic option.